Journal article
Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
Abstract
BACKGROUND: Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis.
METHODS: In two phase 3, double-blind, 52-week trials, ERASURE (Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis) and FIXTURE (Full Year Investigative Examination of Secukinumab vs. Etanercept …
Authors
Langley RG; Elewski BE; Lebwohl M; Reich K; Griffiths CEM; Papp K; Puig L; Nakagawa H; Spelman L; Sigurgeirsson B
Journal
The New England Journal of Medicine, Vol. 371, No. 4, pp. 326–338
Publisher
Massachusetts Medical Society
Publication Date
July 24, 2014
DOI
10.1056/nejmoa1314258
ISSN
0028-4793